Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion (NAPA-3)

Next Previous
Trial Profile

Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion (NAPA-3)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms NAPA-3
  • Sponsors Nuvelo

    • Most Recent Events

    • 02 Aug 2022 This trial has been completed in Netherland and Hungary (End Date: 26 Jun 2007), according to European Clinical Trials Database record.
    • 01 Mar 2010 Primary endpoint results published in the Journal of Vascular Surgery
    • 14 Jan 2008 Status changed from in progress to discontinued.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top